AI Engines For more Details: Perplexity Kagi Labs You
Central Nervous System Effects: Azacyclonol exerts its primary effects on the central nervous system, where it acts as a sedative and tranquilizer. It may help alleviate symptoms of anxiety, agitation, and tension by promoting relaxation and calming effects.
Anticholinergic Properties: Azacyclonol possesses anticholinergic properties, meaning it can inhibit the activity of acetylcholine, a neurotransmitter involved in various physiological processes. Anticholinergic effects may include dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment.
Side Effects: Common side effects associated with azacyclonol may include drowsiness, dizziness, fatigue, confusion, headache, gastrointestinal disturbances, and allergic reactions. Some individuals may experience paradoxical reactions, such as increased agitation or excitability.
Cardiovascular Effects: Azacyclonol may cause changes in heart rate and blood pressure, particularly at higher doses. Patients with cardiovascular conditions should use azacyclonol cautiously and under the supervision of a healthcare professional.
Psychiatric Conditions: Azacyclonol has been used in the treatment of various psychiatric conditions, including anxiety disorders, psychotic disorders, and behavioral disturbances. However, its efficacy and safety profile compared to other medications have led to its limited use in modern psychiatric practice.
Drug Interactions: Azacyclonol may interact with other medications, particularly those with central nervous system depressant effects or anticholinergic properties. Concurrent use of azacyclonol with alcohol or other sedative-hypnotic drugs may potentiate central nervous system depression and increase the risk of adverse effects.
Limited Use: Due to concerns regarding side effects, drug interactions, and the availability of alternative treatment options, the use of azacyclonol has declined in recent years. Healthcare providers may consider other pharmacological and non-pharmacological interventions for managing psychiatric symptoms.
Monitoring and Dosage: Patients receiving azacyclonol therapy should be closely monitored for therapeutic response and adverse effects. Dosage adjustments may be necessary based on individual tolerance and treatment goals.
Pregnancy and Lactation: The safety of azacyclonol use during pregnancy and lactation has not been well established. Pregnant or breastfeeding individuals should consult with their healthcare provider before using azacyclonol.
Withdrawal Effects: Abrupt discontinuation of azacyclonol therapy may result in withdrawal symptoms, including rebound anxiety, insomnia, agitation, and other withdrawal reactions. Tapering the dosage under medical supervision may help minimize the risk of withdrawal effects.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 2 | 0.9 | 1.22 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.1 | 1.4 | -0.27 |
| Allergies | 2.3 | 1.4 | 0.64 |
| Allergy to milk products | 0.7 | 0.7 | 0 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 1.7 | 1.6 | 0.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.4 | 2 |
| Ankylosing spondylitis | 1.2 | 0.6 | 1 |
| Anorexia Nervosa | 1.4 | 1 | 0.4 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 2.1 | 0.9 | 1.33 |
| Atherosclerosis | 0.6 | 0.1 | 5 |
| Atrial fibrillation | 2 | 0.7 | 1.86 |
| Autism | 2.6 | 3.5 | -0.35 |
| Autoimmune Disease | 0.6 | 0.3 | 1 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 1 | 0.9 | 0.11 |
| Brain Trauma | 0.6 | 0.6 | 0 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 1.2 | -1.2 | |
| Carcinoma | 1.7 | 1.2 | 0.42 |
| Celiac Disease | 0.3 | 2.1 | -6 |
| Cerebral Palsy | 0.6 | 0.4 | 0.5 |
| Chronic Fatigue Syndrome | 2.1 | 1.6 | 0.31 |
| Chronic Kidney Disease | 0.8 | 0.6 | 0.33 |
| Chronic Lyme | 0.1 | 0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.9 | -0.13 |
| Chronic Urticaria (Hives) | 0.3 | 0.1 | 2 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.7 | 0 |
| Cognitive Function | 1.4 | 0.6 | 1.33 |
| Colorectal Cancer | 2.6 | 0.3 | 7.67 |
| Constipation | 0.6 | 0.1 | 5 |
| Coronary artery disease | 0.6 | 0.4 | 0.5 |
| COVID-19 | 3.3 | 3.5 | -0.06 |
| Crohn's Disease | 2.2 | 2.3 | -0.05 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 0.8 | 0.6 | 0.33 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 4.4 | 3.8 | 0.16 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.3 | 0.8 | -1.67 |
| Endometriosis | 1.4 | 0.9 | 0.56 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.8 | 1.1 | -0.38 |
| erectile dysfunction | 0.4 | 0.3 | 0.33 |
| Fibromyalgia | 1.6 | 0.5 | 2.2 |
| Functional constipation / chronic idiopathic constipation | 2.5 | 1.4 | 0.79 |
| gallstone disease (gsd) | 0.9 | 0.4 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | -0.6 | |
| Generalized anxiety disorder | 1.1 | 1.6 | -0.45 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.7 | 0 |
| Graves' disease | 1 | 1.3 | -0.3 |
| Gulf War Syndrome | 0.7 | 0.5 | 0.4 |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0.8 | 0.6 | 0.33 |
| Heart Failure | 1.7 | 0.8 | 1.13 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.6 | -0.6 | |
| hypercholesterolemia (High Cholesterol) | 0.1 | -0.1 | |
| hyperglycemia | 0.8 | 1.1 | -0.38 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.4 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 2 | 2.5 | -0.25 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 0.8 | 0.3 | 1.67 |
| IgA nephropathy (IgAN) | 1.3 | 0.7 | 0.86 |
| Inflammatory Bowel Disease | 2.4 | 3.3 | -0.38 |
| Insomnia | 0.9 | 1.2 | -0.33 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 1.2 | 2.1 | -0.75 |
| ischemic stroke | 2.1 | 2.1 | |
| Liver Cirrhosis | 2.3 | 2 | 0.15 |
| Long COVID | 2.4 | 3.5 | -0.46 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.6 | -0.6 | |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 0.3 | 0.5 | -0.67 |
| ME/CFS without IBS | 0.8 | 0.4 | 1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1 | 0.1 | 9 |
| Metabolic Syndrome | 2.1 | 3 | -0.43 |
| Mood Disorders | 4.5 | 3.5 | 0.29 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.1 | 4 |
| Multiple Sclerosis | 3.1 | 2.2 | 0.41 |
| Multiple system atrophy (MSA) | 0.3 | 0.7 | -1.33 |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.3 | 1.2 | -3 |
| Neuropathy (all types) | 0.8 | 0.4 | 1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 2.3 | -0.64 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.3 | 2 |
| Obesity | 3.3 | 4.1 | -0.24 |
| obsessive-compulsive disorder | 1.7 | 1.1 | 0.55 |
| Osteoarthritis | 0.8 | 1 | -0.25 |
| Osteoporosis | 0.6 | 0.6 | 0 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 3.2 | 2.2 | 0.45 |
| Polycystic ovary syndrome | 2.5 | 1.6 | 0.56 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.8 | 1.3 | -0.63 |
| Psoriasis | 1.1 | 1 | 0.1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.6 | 0.7 | 4.14 |
| Rosacea | 0.6 | 0.3 | 1 |
| Schizophrenia | 3.2 | 1.8 | 0.78 |
| scoliosis | 0.3 | 0.7 | -1.33 |
| Sjögren syndrome | 0.9 | 0.9 | 0 |
| Sleep Apnea | 1.3 | 1 | 0.3 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | 0 |
| Stress / posttraumatic stress disorder | 0.8 | 1.4 | -0.75 |
| Systemic Lupus Erythematosus | 1.4 | 1.2 | 0.17 |
| Tic Disorder | 0.6 | 0.3 | 1 |
| Tourette syndrome | 0.4 | 0.4 | |
| Type 1 Diabetes | 1.2 | 2.2 | -0.83 |
| Type 2 Diabetes | 2.1 | 2.4 | -0.14 |
| Ulcerative colitis | 1.9 | 1.6 | 0.19 |
| Unhealthy Ageing | 0.9 | 1.1 | -0.22 |
| Vitiligo | 1.6 | 1 | 0.6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
